Targeting secretory leukocyte protease inhibitor (SLPI) inhibits colorectal cancer cell growth, migration and invasion via downregulation of AKT
Authors:
Open Access
Abstract
The secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor which plays important role in bacterial infection, inflammation, wound healing and epithelial proliferation. Dysregulation of SLPI has been reported in a variety of human cancers including glioblastoma, lung, breast, ovarian and colorectal carcinomas and is associated with tumor aggressiveness and metastatic potential. However, the pathogenic role of SLPI in colorectal cancer is still unclear. Here we showed that SLPI mRNA level was significantly upregulated in colorectal cancer tissues compared to adjacent normal controls. Targeting SLPI by siRNA inhibited proliferation, migration and invasion of colorectal cancer cells lines HT29 and HT116 in vitro. Mechanistically, blockage of cancer cell growth and metastasis after SLPI knockdown was associated with down-regulation of AKT signaling. In conclusion, SLPI regulated colorectal cell growth and metastasis via AKT signaling. SLPI may be a novel biomarker and therapeutic target for colorectal cancer. Targeting AKT signaling may be effective for colorectal cancer treatment.Keywords
This publication has 36 references indexed in Scilit:
- Health-Related Quality of Life Among Long-Term Survivors of Colorectal Cancer: A Population-Based StudyThe Oncologist, 2011
- Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cellsGynecologic Oncology, 2011
- Secretory Leukocyte Protease Inhibitor (SLPI) Expression and Tumor Invasion in Oral Squamous Cell CarcinomaThe American Journal of Pathology, 2011
- Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer CellsClinical Cancer Research, 2010
- Overexpression of a secretory leukocyte protease inhibitor in human gastric cancerInternational Journal of Cancer, 2008
- Secretory leukocyte peptidase inhibitor and lung cancerCancer Science, 2008
- The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood‐borne metastasis via an invasion‐independent pathwayThe Journal of Pathology, 2007
- The role of secretory leucoprotease inhibitor in the resolution of inflammatory responsesBiochemical Society Transactions, 2007
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Inhibition of Murine Neutrophil Serine Proteinases by Human and Murine Secretory Leukocyte Protease InhibitorBiochemical and Biophysical Research Communications, 1999